Trial Profile
A phase III study of vobarilizumab in patients with rheumatoid arthritis
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2016
Price :
$35
*
At a glance
- Drugs Vobarilizumab (Primary)
- Indications Rheumatoid arthritis; Systemic lupus erythematosus
- Focus Therapeutic Use
- 20 Oct 2016 According to Ablynx media release, the first patient is expected to be enrolled by the end of 2017.
- 09 Aug 2016 According to an Ablynx media release, company expects to initiate Phase III programme with vobarilizumab in Rheumatoid-arthritis before the end of the year 2016.
- 05 Oct 2015 New trial record